Trial reportJournal of cellular and molecular medicine2022
A randomized, placebo-controlled clinical trial of hydrogen/oxygen inhalation for non-alcoholic fatty liver disease.
Trial report in Journal of cellular and molecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- A randomized, placebo-controlled clinical trial of hydrogen/oxygen inhalation for non-alcoholic fatty liver disease.Journal of cellular and molecular medicine · 2022Trial
- Molecular Hydrogen as a Regulator of Mitochondrial Quality Control and Metabolic Reprogramming.International journal of molecular sciences · 2026Review
- Integrated Machine Learning and Multi-Omics Analysis Identifies Mitophagy-Related Core Genes and Mechanisms in Non-Alcoholic Fatty Liver Disease.Journal of inflammation research · 2026Article
- Molecular mechanisms associated with effects of hydrogen molecule in liver diseases: the review of current evidence.European journal of medical research · 2025Review
- Gas as medicine: the case for hydrogen gas as a therapeutic agent for critical illness.Intensive care medicine experimental · 2025Article
- Molecular Hydrogen Therapy: Mechanisms, Delivery Methods, Preventive, and Therapeutic Application.MedComm · 2025Review
- Article
- Effects of hydrogen-rich water on blood uric acid in patients with hyperuricemia: A randomized placebo-controlled trial.Heliyon · 2024Article
- Hydrogen-Rich Water (HRW) Reduces Fatty Acid-Induced Lipid Accumulation and Oxidative Stress Damage through Activating AMP-Activated Protein Kinase in HepG2 Cells.Biomedicines · 2024Article
- Zn-Fe primary battery-enabled controlled hydrogen release in stomach for improving insulin resistance in obesity-associated type 2 diabetes.Bioactive materials · 2024Article
- The impact of hydrogen-rich water on liver enzyme levels in clinical populations: a comprehensive review and meta-analysis.Gastroenterology and hepatology from bed to bench · 2024Review
- Effectiveness and safety of hydrogen inhalation therapy as an additional treatment for hypertension in real-world practice: a retrospective, observational study in China.Frontiers in cardiovascular medicine · 2024Article
- Molecular Hydrogen Therapy-A Review on Clinical Studies and Outcomes.Molecules (Basel, Switzerland) · 2023Review
- Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, and Metabolic Repercussions: The Vicious Cycle and Its Interplay with Inflammation.International journal of molecular sciences · 2023Review
- Therapeutic Potential of Molecular Hydrogen in Metabolic Diseases from Bench to Bedside.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Therapeutic Inhalation of Hydrogen Gas for Alzheimer's Disease Patients and Subsequent Long-Term Follow-Up as a Disease-Modifying Treatment: An Open Label Pilot Study.Pharmaceuticals (Basel, Switzerland) · 2023Article
- What's New in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD).Journal of clinical medicine · 2023Review
- The effect of a low dose hydrogen-oxygen mixture inhalation in midlife/older adults with hypertension: A randomized, placebo-controlled trial.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide with increasing incidence consistent with obesity, type 2 diabetes and cardiovascular diseases. No approved medication was currently available for NAFLD treatment. Molecular hydrogen (H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.